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Abstract: Gastric carcinoma MKN45 cells stably transfected with the full-length ST3GAL4 gene were 
characterised by glycomic and sialoproteomic analysis. Complementary strategies were applied to 
assess the glycomic alterations induced by ST3GAL4 overexpression. The N- and O-glycome data were 
generated in two parallel structural analyses, based on PGC-ESI-MS/MS. Data on glycan structure 
identification and relative abundance in ST3GAL4 overexpressing cells and respective mock control are 
presented. The sialoproteomic analysis based on titanium-dioxide enrichment of sialopeptides with 
subsequent LC-MS/MS identification was performed. This analysis identified 47 proteins with 
significantly increased sialylation. The data in this article is associated with the research article published 
in Biochim Biophys Acta “Glycomic analysis of gastric carcinoma cells discloses glycans as modulators of 
RON receptor tyrosine kinase activation in cancer “ [1]. 
 
Specifications Table 
Subject area Biology 
More specific subject area Glycobiology in cancer 
Type of data Tables 
How data was acquired N- and O-glycome analysed by PGC-LC ESI MS/MS performed on an LTQ ion 
trap mass spectrometer and PGC-nanoLC ESI MS/MS performed on an 
amaZon ETD Speed ion trap. Sialoproteome performed using Easy-nLC II 
system and Orbitrap Fusion Tribrid system. 
Data format Analyzed 
Experimental factors MKN 45 cells stably transfected with the full-length ST3GAL4 gene or empty 
vector (mock). 
Experimental features MKN 45 cells grown in vitro in RPMI medium with 10% FBS. 
Data source location Not applicable 
Data accessibility Data is within this article. 
 
 
 
Value of the data 
 Data shows the N- and O-glycome of the MKN45 gastric carcinoma cells and ST3GAL4 
sialyltransferase overexpressing cells. 
 Data provides a list of glycoproteins with altered sialylated N-glycans in ST3GAL4 
overexpressing cells, including several cancer associated proteins. 
 These data are valuable as a source for novel biomarkers for gastric cancer. 
 
Data 
This data article includes the N- and O-glycome of MKN45 cells and assesses the glycosylation alterations 
induced by ST3GAL4 overexpression. In addition, we provide the data on the proteins with significant 
increased sialylated N-glycans upon ST3GAL4 overexpression. 
 
Experimental Design, Materials and Methods 
 
Glycomic and sialoproteomic analyses were performed as described below comparing MKN45 cells 
stably transfected with the full-length ST3GAL4 gene or empty vector (mock). Glycome data and 
statistical evaluation are shown in tables 1, 2, 3 and 4. Sialoproteome data and statistical evaluation are 
shown in tables 5 and 6. 
 
1. N-glycomic strategy I: Sample preparation and PGC LC-ESI-MS/MS   
Frozen cell pellets (107 cells) of mock or ST3GAL4 transfected MKN45 cells [2] were directly resuspended 
in 7 M urea, 2 M thiourea, 40 mM Tris, 2% CHAPS, 10 mM DTT and 1% protease inhibitor (Sigma-Aldrich, 
St. Louis, MO). The cell membranes were disrupted by 10 times 10 sec sonication with 16 amplitudes 
and 1 minute on ice in between, and subsequent shaking at 4°C overnight. To reduce the viscosity of the 
lysates, the DNA was degraded by adding 1 µl benzonase® nuclease (250 units, Sigma-Aldrich) and 30 
min incubation on 37°C. In order to impair refolding of proteins, 25 mM iodoacetamide were added for 
alkylation during 1 h in the dark. The lysates were centrifuged for 30 min at 14,000 rpm and the 
supernatants were transferred to a fresh tube.  
Then, solubilized proteins were concentrated by adding 150 µl of supernatant on a 10 kDa cut-off 
spinfilter (PALL, Port Washington, NY), spinning down for 5 min with 12,000 x g and washing 3 times 
with 100 µl 50 mM NH4HCO3, pH 8.4. N-linked oligosaccharides were released in the spinfilter using 20 
µl 50 mM NH4HCO3 and PNGase F (5 mU, Prozyme, Hayward, CA) with incubation at 37°C overnight. 
Subsequently, the N-glycans were collected by washing 3 times with 20 µl H2O and dried in Speedvac. 
Reactions were quenched with 1 µl of glacial acetic acid and N-glycan samples were desalted and dried 
as previously described [3]. N-glycan samples were subjected to LC-ESI-MS/MS analysis using a 10 cm x 
250 µm I.D. column, prepared in-house, containing 5 µm porous graphitized carbon (PGC) particles 
(Thermo Scientific, Waltham, MA). Glycans were eluted using a linear gradient from 0 to 40% 
acetonitrile in 10 mM NH4HCO3 over 40 min at a flow rate of 10 μl/min. The eluted N-glycans were 
detected using a LTQ ion trap mass spectrometer (Thermo Scientific) in negative-ion mode with an 
electrospray voltage of 3.5 kV, capillary voltage of −33.0 V and capillary temperature of 300°C. Air was 
used as a sheath gas and mass ranges were defined dependent on the specific structure to be analyzed. 
The data were processed using the Xcalibur software (version 2.0.7, Thermo Scientific) and manually 
interpreted from their MS/MS spectra.  
Optionally prior to analysis N-glycan were digested in 50 mM sodium phosphate, pH 6.0 at 37°C 
overnight using sialidase S (4 mU, ProZyme) that releases α2-3 linked non-reducing terminal sialic acids 
(recombinant sialidase from Streptococcus pneumoniae, expressed in Escherichia coli) and sialidase A (5 
mU, ProZyme) that releases α2-3/6/8 linked non-reducing terminal sialic acid (recombinant gene from 
Arthrobacter ureafaciens, expressed in Escherichia coli) to confirm sialic acid linkage. 
All analyses were performed in three independent replicates and results were subjected to statistical 
analyses (Average, standard deviation and unpaired T-test).  
 
Table 1: Identified N-glycan structures I 
Structures are represented by the mass to charge ratio (m/z) in which they were identified and 
quantified, by monosaccharide composition and proposed structure based on MS/MS analyses. The 
relative quantities were determined by base-peak intensity of extracted ion chromatograms. The 
average value (Avg) and standard deviation (SD) of triplicates are shown, as well as the p-value (T-test; * 
p<0.05; ** p<0.01; *** p<0.001). Increased or decreased relative abundance are shown in red or blue, 
respectively. Structures marked as not analyzed (na) were either not detected or overlapped with other 
structures in given sample, precluding their quantification. Unknown linkage is represented by “?”.  
 
m/z 
 Composition 
Proposed 
structure 
Mock replicates (n=3) ST3GAL4 replicates (n=3) 
 
z=1 z=2 % % % Avg SD % % % Avg SD p-value 
708 / HexNAc1Hex3 
 
0.04 0.02 0.2 0.09 0.10 0.08 0.08 0.03 0.06 0.03 0.3636 
749 / HexNAc2Hex2  
 
0.36 0.3 0.3 0.32 0.03 0.3 0.29 0.23 0.27 0.04 0.0955 
895 / HexNAc2Hex2Fuc1 
 
1.18 0.95 1.58 1.24 0.32 0.75 0.69 1.38 0.94 0.38 0.181 
911 / HexNAc2Hex3 
 
0.17 0.27 1.27 0.57 0.61 0.32 0.39 0.37 0.36 0.04 0.3054 
911 / HexNAc2Hex3 
 
0.02 0.03 0.45 0.17 0.25 0.07 0.09 0.13 0.10 0.03 0.3356 
911 / HexNAc2Hex3 
 
0.1 0.09 0.04 0.08 0.03 0.09 0.09 0.06 0.08 0.02 0.4421 
1057 / HexNAc2Hex3Fuc1 
 
0.96 0.84 2.28 1.36 0.80 0.75 0.65 0.98 0.79 0.17 0.1719 
1073 / HexNAc2Hex4 
 
0.06 0.12 0.68 0.29 0.34 0.11 0.13 0.12 0.12 0.01 0.2437 
1073 / HexNAc2Hex4 
 
0.3 0.25 0.18 0.24 0.06 0.23 0.3 0.13 0.22 0.09 0.3604 
1202 / 2HexNAc3Hex1Sia 
 
2.29 2.24 6.23 3.59 2.29 1.94 3.09 3.34 2.79 0.75 0.3077 
1202 / HexNAc2Hex3Sia1 
 
0.29 0.21 0.69 0.40 0.26 0.18 0.28 0.48 0.31 0.15 0.33 
1235 / HexNAc2Hex5 
 
0.41 0.45 0.24 0.37 0.11 0.41 0.55 0.24 0.40 0.16 0.3896 
1235 / HexNAc2Hex5 
 
0.2 0.17 0.09 0.15 0.06 0.17 0.21 0.07 0.15 0.07 0.4765 
1235 / HexNAc2Hex5 
 
1.53 1.25 2.26 1.68 0.52 1.81 1.8 2.55 2.05 0.43 0.1974 
1364 681 HexNAc2Hex4Sia1 
 
1.2 1.28 2.29 1.59 0.61 0.85 1.28 1.25 1.13 0.24 0.1592 
1397 698 HexNAc2Hex6 
 
0.26 0.24 0.28 0.26 0.02 0.3 0.33 0.25 0.29 0.04 0.1463 
1397 698 HexNAc2Hex6 
 
9.32 8.64 7.54 8.50 0.90 7.52 8.27 6.52 7.44 0.88 0.1082 
1422 711 HexNAc3Hex4Fuc1 
 
na na 1.29 1.29 / na na 0.49 0.49 / n/a 
1422 711 HexNAc3Hex4Fuc1 
 
na na 0.41 0.41 / na na 0.22 0.22 / n/a 
1438 719 HexNAc3Hex5 
 
na na 0.31 0.31 / na na 0.2 0.20 / n/a 
1559 779 HexNAc2Hex7 
 
0.25 0.24 0.17 0.22 0.04 0.32 0.37 0.19 0.29 0.09 0.1542 
1559 779 HexNAc2Hex7 
 
6.14 6.24 4.61 5.66 0.91 4.72 5.47 3.41 4.53 1.04 0.116 
1559 779 HexNAc2Hex7 
 
3.71 3.39 3.28 3.46 0.22 3.15 3.45 2.79 3.13 0.33 0.1173 
1567 783 HexNAc3Hex3Sia1 
 
na na 0.6 0.60 / 0 0 0 0.00 0.00 n/a 
1567 783 HexNAc3Hex4Sia1 
 
na na 0.7 0.70 / na na 0.63 0.63 / n/a 
1584 792 HexNAc3Hex5Fuc1 
 
na na 0.63 0.63 / na na 0.57 0.57 / n/a 
1600 800 HexNAc3Hex6 
 
na na 0.52 0.52 / na na 0.59 0.59 / n/a 
1713 856 HexNAc3Hex4Sia1Fuc1 
 
7.34 5.42 8.25 7.00 1.44 4.71 3.79 6.94 5.15 1.62 0.1067 
1721 860 HexNAc2Hex8 
 
9.65 9.88 6.89 8.81 1.66 8.53 10.15 5.82 8.17 2.19 0.3544 
1729 864 HexNAc3Hex5Sia1 
 
0.95 1.59 3.19 1.91 1.15 1.19 1.48 1.77 1.48 0.29 0.2944 
1729 864 HexNAc3Hex5Sia1 
 
0.96 1 1.36 1.11 0.22 1.02 0.89 1.15 1.02 0.13 0.2978 
1729 864 HexNAc3Hex5Sia1 
 
na na 0.8 0.80 
#DIV/
0! 
na na 1.09 1.09 / n/a 
1729 864 HexNAc3Hex5Sia1 
 
0 0 0 0.00 0.00 na na 0.58 0.58 / n/a 
1746 873 HexNAc3Hex6Fuc1 
 
na na 0.41 0.41 / na na 0.32 0.32 / n/a 
1787 893 HexNAc4Hex5Fuc1 
 
0.39 0.41 1.7 0.83 0.75 0.38 0.27 0.63 0.43 0.18 0.2247 
/ 922 HexNAc5Hex5 
 
0.06 0.1 0.09 0.08 0.02 0 0.01 0 0.00 0.01 
0.0081 
** 
/ 937 HexNAc3Hex5Sia1Fuc1 
 
1.74 1.45 1.48 1.56 0.16 1.83 1.3 2.04 1.72 0.38 0.2703 
/ 941 HexNAc2Hex9 
 
3.31 3.36 2.63 3.10 0.41 3.32 3.74 2.36 3.14 0.71 0.4687 
/ 945 HexNAc3Hex6Sia1 
 
1.44 1.31 1.12 1.29 0.16 1.51 1.32 1.62 1.48 0.15 0.1024 
/ 945 HexNAc3Hex6Sia1 
 
0.04 0.03 0 0.02 0.02 0.3 0.27 0.35 0.31 0.04 
0.0009 
*** 
/ 966 HexNAc4Hex5Sia1 
 
0.87 0.78 0.71 0.79 0.08 0.98 0.96 0.73 0.89 0.14 0.1706 
/ 995 HexNAc5Hex5Fuc1 
 
na na 0.74 0.74 / na na 0.15 0.15 / n/a 
/ 1010 HexNAc3Hex5Sia2 
 
7.58 9.96 7.37 8.30 1.44 5.23 7.11 6.89 6.41 1.03 0.0723 
/ 1010 HexNAc3Hex5Sia2 
 
3.17 3.43 1.89 2.83 0.82 5.67 6.23 6.69 6.20 0.51 
0.0034 
** 
/ 1010 HexNAc3Hex5Sia2 
 
1.24 1.1 0.25 0.86 0.54 3.07 2.89 4.24 3.40 0.73 
0.0052 
** 
/ 1018 HexNAc3Hex6Sia1Fuc1 
 
1.04 0.82 0.86 0.91 0.12 0.96 0.98 1.07 1.00 0.06 0.1464 
/ 1022 HexNAc2Hex10 
 
0.37 0.38 0.38 0.38 0.01 0.39 0.37 0.39 0.38 0.01 0.2191 
/ 1039 HexNAc4Hex5Sia1Fuc1 
 
3.73 3.32 5.22 4.09 1.00 3.86 3.45 5.57 4.29 1.12 0.4133 
/ 1039 HexNAc4Hex5Sia1Fuc1 
 
0.19 0.06 0.55 0.27 0.25 0.97 0.62 1.51 1.03 0.45 
0.0389 
* 
/ 1067 HexNAc5Hex5Sia1 
 
0.45 0.56 na 0.51 0.08 0.1 0.04 na 0.07 0.04 
0.0189 
* 
/ 1111 HexNAc4Hex5Sia2 
 
1.78 2.37 na 2.08 0.42 0.09 0.15 na 0.12 0.04 
0.0463 
* 
/ 1111 HexNAc4Hex5Sia2 
 
5.39 5.23 na 5.31 0.11 5.49 7.31 na 6.40 1.29 0.2209 
/ 1111 HexNAc4Hex5Sia2 
 
1.74 1.92 na 1.83 0.13 2.18 1.4 na 1.79 0.55 0.4677 
/ 1111 HexNAc4Hex5Sia2 
 
0.18 0.2 na 0.19 0.01 1.41 0.98 na 1.20 0.30 0.0668 
/ 1140 HexNAc5Hex5Sia1Fuc1 
 
2.01 2.54 na 2.28 0.37 0.33 0.24 na 0.29 0.06 
0.0385 
* 
/ 1184 HexNAc4Hex5Sia2Fuc1 
 
9.37 9 7.91 8.76 0.76 7.41 5.95 7.95 7.10 1.03 
0.0475 
* 
/ 1184 HexNAc4Hex5Sia2Fuc1 
 
2.52 2.81 2.25 2.53 0.28 7.47 4.87 7.03 6.46 1.39 
0.0175 
* 
/ 1184 HexNAc4Hex5Sia2Fuc1 
 
0.38 0.54 0.23 0.38 0.16 6.22 4.33 5.88 5.48 1.01 
0.0057 
** 
/ 1213 HexNAc5Hex5Sia1Fuc2 
 
1.27 1.06 0.85 1.06 0.21 0.12 0.1 0 0.07 0.06 
0.0048 
** 
/ 1213 HexNAc5Hex5Sia2 
 
1.08 1.13 0.98 1.06 0.08 0.17 0.18 0 0.12 0.10 
0.0002 
*** 
/ 1221 HexNAc5Hex6Sia1Fuc1 
 
0.96 1.02 na 0.99 0.04 0.99 0.75 na 0.87 0.17 0.2474 
/ 1286 HexNAc5Hex5Sia2Fuc1 
 
na na 2.76 2.76 / 0 0 0 0.00 0.00 n/a 
Total: 100 100 100 
  
100 100 100 
   
 
 
 
 
 
2. N-glycomic strategy II: Sample preparation and PGC nanoLC-ESI MS/MS 
Frozen cell pellets (107 cells) of mock or ST3GAL4 transfected MKN45 cells were directly resuspended in 
2 mL of lysis buffer (50 mM Tris-HCl, 100 mM NaCl, 1 mM EDTA and protease inhibitor at pH 7.4) and 
stored on ice for 20 min. The cells were lysed using a Polytron homogenizer for at least three times for 
10 seconds in a cold room. Cellular debris and unlysed cells were sedimented by centrifugation at 2,000 
g for 20 min at 4°C. The supernatant was collected and the pellets re-suspended in 1 mL of lysis buffer 
and centrifuged again at 2,000 g for 20 min at 4°C. All the supernatants were combined, diluted in 20 
mM Tris-HCl (pH 7.4) and ultracentrifuged at 120,000 g for 90 min at 4°C. The supernatant was 
separated from the pellet containing the cell membrane proteins. The membrane proteins were 
resuspended with 150 μL of 100 mM ammonium bicarbonate buffer and lyophilized overnight. The dried 
samples were solubilized in 50 μL of 8 M urea and 10 µL aliquots were dot-blotted onto PVDF 
membranes as described previously [4]. N- and O-glycan release as well as PGC-nanoLC ESI MS/MS 
analysis on an amaZon ETD Speed ion trap (Bruker, Bremen, Germany) were performed as described in 
detail previously [4, 5]. 
Table 2: Identified N-glycan structures II 
Structures are represented by their [M – H] value and charge state in which they were identified and 
quantified, by monosaccharide composition and proposed structure based on MS/MS analyses. The 
relative quantities were determined by base-peak intensity of extracted ion chromatograms. The ratio of 
glycan abundance in ST3GAL4 transfected cells relative to mock transfected is shown on the right 
column. Increases or decreases larger than 2 fold in glycan abundance are highlighted red or blue, 
respectively. 
[M-H]- z Composition Proposed structure mock ST3GAL4 ST3GAL4/mock 
1073.44 1 HexNAc2Hex4 
 
0.26 0.23 0.91 
1235.48 1 HexNAc2Hex5 
 
0.35 0.31 0.87 
1235.5 1 HexNAc2Hex5 
 
0.47 0.59 1.25 
1235.54 1 HexNAc2Hex5 
 
1.21 1.30 1.08 
1397.52 1 HexNAc2Hex6 
 
0.37 0.31 0.83 
1397.56 1 HexNAc2Hex6 
 
4.06 2.67 0.66 
1559.64 2 HexNAc2Hex7 
 
2.18 1.72 0.79 
1559.69 2 HexNAc2Hex7 
 
4.66 3.36 0.72 
1713.82 2 HexNAc3Hex4Sia1Fuc1 
 
1.61 1.52 0.94 
1721.69 2 HexNAc2Hex8 
 
0.06 0.11 1.84 
1721.72 2 HexNAc2Hex8 
 
0.21 0.16 0.80 
1721.78 2 HexNAc2Hex8 
 
14.36 12.98 0.90 
1729.76 2 HexNAc3Hex5Sia1 
 
0.43 0.41 0.95 
1787.79 2 HexNAc4Hex5Fuc1 
 
0.87 0.69 0.80 
1875.78 2 HexNAc3Hex5Sia1Fuc1 
 
2.99 2.51 0.84 
1875.89 2 HexNAc3Hex5Sia1Fuc1 
 
0.00 0.63 / 
1883.74 2 HexNAc2Hex9 
 
11.94 11.97 1.00 
1883.75 2 HexNAc2Hex9 
 
2.40 2.19 0.91 
1891.78 2 HexNAc3Hex6Sia1 
 
2.26 2.11 0.93 
1932.80 2 HexNAc4Hex5Sia1 
 
0.97 0.65 0.67 
1990.84 2 HexNAc5Hex5Fuc1 
 
0.85 0.00 0.00 
2037.83 2 HexNAc3Hex6Sia1Fuc1 
 
1.23 0.90 0.73 
2045.73 2 HexNAc1Hex10 
 
2.05 2.16 1.05 
2053.70 2 HexNAc3Hex7Sia1Fuc1 
 
0.49 0.28 0.57 
2078.80 2 HexNAc4Hex5Sia1Fuc1 
 
0.91 1.20 1.32 
2078.85 2 HexNAc4Hex5Sia1Fuc1 
 
1.48 0.58 0.39 
2078.90 2 HexNAc4Hex5Sia1Fuc1 
 
11.24 7.82 0.70 
2119.83 2 HexNAc5Hex4Sia1Fuc1 
 
1.07 0.00 0.00 
2223.85 2 HexNAc4Hex5Sia2 
 
1.38 1.62 1.17 
2223.87 2 HexNAc4Hex5Sia2 
 
0.00 0.45 / 
2223.89 2 HexNAc4Hex5Sia2 
 
0.34 0.72 2.12 
2224.92 2 HexNAc4Hex5Sia1Fuc2 
 
5.64 3.56 0.63 
2281.82 2 HexNAc5Hex5Sia1Fuc1 
 
0.28 0.00 0.00 
2281.89 2 HexNAc5Hex5Sia1Fuc1 
 
1.97 0.32 0.16 
2369.88 2 HexNAc4Hex5Sia2Fuc1 
 
1.31 6.45 4.93 
2369.91 2 HexNAc4Hex5Sia2Fuc1 
 
0.00 5.26 / 
2369.97 2 HexNAc4Hex5Sia2Fuc1 
 
8.23 8.53 1.04 
2410.85 2 HexNAc5Hex4Sia2Fuc1 
 
0.16 0.14 0.90 
2410.91 2 HexNAc5Hex4Sia2Fuc1 
 
0.00 0.49 / 
2426.89 2 HexNAc5Hex5Sia2 
 
0.35 0.00 0.00 
2427.87 2 HexNAc5Hex5Sia1Fuc2 
 
1.29 0.10 0.07 
2443.86 2 HexNAc5Hex6Sia1Fuc1 
 
0.17 0.35 2.05 
2443.87 2 HexNAc5Hex6Sia1Fuc1 
 
0.00 0.10 / 
2443.89 2 HexNAc5Hex6Sia1Fuc1 
 
0.41 0.15 0.38 
2443.90 2 HexNAc5Hex6Sia1Fuc1 
 
0.54 0.46 0.84 
2443.91 2 HexNAc5Hex6Sia1Fuc1 
 
1.21 1.58 1.31 
2443.95 2 HexNAc5Hex6Sia1Fuc1 
 
1.12 0.00 0.00 
2444.17 2 HexNAc5Hex6Sia1Fuc1 
 
0.00 0.84 / 
2515.91 2 HexNAc4Hex5Sia2Fuc2 
 
0.00 0.55 / 
2516.01 2 HexNAc4Hex5Sia2Fuc2 
 
0.00 0.91 / 
2572.95 2 HexNAc5Hex5Sia2Fuc1 
 
1.81 0.25 0.14 
2572.97 2 HexNAc5Hex5Sia2Fuc1 
 
0.00 1.16 / 
2572.97 2 HexNAc5Hex5Sia2Fuc1 
 
0.00 1.37 / 
2662.01 2 HexNAc4Hex5Sia2Fuc3 
 
0.00 0.33 / 
2734.91 2 HexNAc5Hex6Sia2Fuc1 
 
0.72 0.72 0.99 
2734.96 2 HexNAc5Hex6Sia2Fuc1 
 
0.33 0.40 1.21 
2734.96 2 HexNAc5Hex6Sia2Fuc1 
 
0.38 0.67 1.74 
2734.99 2 HexNAc5Hex6Sia2Fuc1 
 
0.44 0.18 0.40 
2735.00 2 HexNAc5Hex6Sia2Fuc1 
 
0.00 0.45 / 
2735.03 2 HexNAc5Hex6Sia2Fuc1 
 
 
0.51 0.40 0.79 
2735.04 2 HexNAc5Hex6Sia2Fuc1 
 
0.00 0.60 / 
2735.08 2 HexNAc5Hex6Sia2Fuc1 
 
0.31 0.00 0.00 
2880.98 2 HexNAc5Hex6Sia2Fuc2 
 
0.00 0.48 / 
3025.85 2 HexNAc5Hex6Sia3Fuc1 
 
0.00 0.78 / 
3026.03 2 HexNAc5Hex6Sia3Fuc1 
 
0.14 0.27 1.97 
 
 
 
3. O-glycomic strategy I: Sample preparation and LC-ESI-MS/MS analyses 
 
After the removal of N-glycan, as previously described in “1. N-glycomic strategy I: Sample preparation 
and LC-ESI-MS/MS analyses”, the O-linked glycans were released from retained glycoproteins in 
spinfilter using reductive β-elimination (0.5 M NaBH4, 50 mM NaOH at 50°C, 16h). Reactions were 
quenched with 1 µl of glacial acetic acid and glycan samples were desalted and dried as previously 
described [3]. Glycans were subjected to LC-ESI-MS/MS analysis using a 10 cm x 250 µm I.D. column, 
prepared in-house, containing 5 µm porous graphitized carbon (PGC) particles (Thermo Scientific. 
Waltham. MA). Glycans were eluted using a linear gradient from 0 to 40% acetonitrile in 10 mM 
NH4HCO3 over 40 min at a flow rate of 10 μl/min. The eluted O-glycans were detected using a LTQ ion 
trap mass spectrometer (Thermo Scientific) in negative-ion mode with an electrospray voltage of 3.5 kV, 
capillary voltage of −33.0 V and capillary temperature of 300°C. Air was used as a sheath gas and mass 
ranges were defined dependent on the specific structure to be analyzed. The data were processed using 
the Xcalibur software (version 2.0.7. Thermo Scientific) and manually interpreted from their MS/MS 
spectra.  
 
Table 3: Identified O-glycan structures I 
Structures are represented by the mass to charge ratio (m/z) in which they were identified and 
quantified, by monosaccharide composition and proposed structure based on MS/MS analyses. The 
relative quantities were determined by base-peak intensity of extracted ion chromatograms. The 
average value (Avg) and standard deviation (SD) of triplicates are shown, as well as the p-value (T-test; * 
p<0.05; ** p<0.01). Increased or decreased relative abundance are shown in red or blue, respectively. 
Unknown linkage is represented by “?”.  
 
m/z 
Composition 
Proposed 
structure 
Mock replicates (n=3) ST3GAL4 replicates (n=3) 
 
z=1 z=2 % % % Avg SD % % % Avg SD 
p-
value 
384 / HexNAc1Hex1 
 
3.52 0.91 0.95 1.79 1.50 2.65 1.65 1.8 2.03 0.54 0.407 
513 / HexNAc1Sia1 
 
1.52 0.83 0.93 1.09 0.37 0.74 1.39 0.73 0.95 0.38 0.336 
587 / HexNAc2Hex1 
 
1.62 0 0 0.54 0.94 1.34 0 0 0.45 0.77 0.450 
587 / HexNAc2Hex1 
 
0.94 0 0 0.31 0.54 0.6 0 0 0.20 0.35 0.390 
675 / HexNAc1Hex1Sia1 
 
4.79 2.22 1.79 2.93 1.62 3.77 2.13 2.41 2.77 0.88 0.444 
675 / HexNAc1Hex1Sia1 
 
6.13 8.1 5.79 6.67 1.25 9.5 8.99 9.9 9.46 0.46 
0.024 
* 
749 / HexNAc2Hex2 
 
3.59 0.84 0.6 1.68 1.66 2.9 0.38 0.84 1.37 1.34 0.409 
749 / HexNAc2Hex2 
 
1.65 0.88 0.34 0.96 0.66 0.65 0.5 0.57 0.57 0.08 0.210 
878 / HexNAc2Hex1Sia1 
 
6.38 3.46 2.16 4.00 2.16 6.05 4.44 3.43 4.64 1.32 0.344 
895 / HexNAc2Hex2Fuc1 
 
0.74 0 0 0.25 0.43 0.35 0 0 0.12 0.20 0.334 
966 / HexNAc1Hex1Sia2 
 
3.77 11.25 9.05 8.02 3.84 6.32 9.04 9.39 8.25 1.68 0.466 
1040 / HexNAc2Hex2Sia1 
 
8.09 2.82 1.2 4.04 3.60 9.11 3.04 4.93 5.69 3.11 0.290 
1040 / HexNAc2Hex2Sia1 
 
11.86 3.85 2.05 5.92 5.22 11.98 5.77 6.99 8.25 3.29 0.278 
1114 / HexNAc3Hex3 
 
1.77 0 0 0.59 1.02 0.27 0 0 0.09 0.16 0.244 
1114 / HexNAc3Hex3 
 
0.87 0 0 0.29 0.50 0.15 0 0 0.05 0.09 0.248 
1186 / HexNAc2Hex2Sia1Fuc1 
 
0.27 0 0 0.09 0.16 0.37 0 0 0.12 0.21 0.419 
1186 / HexNAc2Hex2Sia1Fuc1 
 
2.26 0 0 0.75 1.30 1.14 0 0 0.38 0.66 0.344 
1331 665 HexNAc2Hex2Sia2 
 
22.75 15.58 15.81 18.05 4.07 41.62 41.5 42.3 41.81 0.43 
0.005 
** 
1477 738 HexNAc2Hex2Sia2Fuc1 
 
0 0 0 0.00 0.00 0.48 0 0 0.16 0.28 0.211 
1696 848 HexNAc3Hex3Sia2 
 
0 8.78 11.34 6.71 5.95 0 3.99 4.64 2.88 2.51 0.061 
1696 848 HexNAc3Hex3Sia2 
 
0 7.09 10.78 5.96 5.48 0 8.65 6.74 5.13 4.54 0.314 
/ 1030 HexNAc4Hex4Sia2 
 
9.38 18.42 22.07 16.62 6.53 0 8.51 5.34 4.62 4.30 
0.033 
* 
/ 1213 HexNAc5Hex5Sia2 
 
8.09 14.96 15.15 12.73 4.02 0 0 0 0.00 0.00 
0.016 
* 
Total: 100 100 100     100 100 100   
  
 
 
 
 
 
 
 
 
 
4. O-glycomic strategy II: Sample preparation and PGC nanoLC-ESI MS/MS 
Sample preparation and analysis were performed as previously described in section “2. N-glycomic 
strategy II: Sample preparation and PGC nanoLC-ESI MS/MS”. 
Table 4: Identified O-glycan structures II 
Structures are represented by their [M – H] value and charge state in which they were identified and 
quantified, by monosaccharide composition, type of core and proposed structure based on MS/MS 
analyses. The relative quantities were determined by base-peak intensity of extracted ion 
chromatograms. The ratio of glycan abundance in ST3GAL4 transfected cells relative to mock 
transfected is shown on the right column. Increases or decreases greater than 1.5 fold in glycan 
abundance are highlighted red or blue, respectively. 
[M-H]- z  Composition Type Assigned structures Mock ST3GAL4 ST3GAL4/mock 
675.30 1 HexNAc1Hex1Sia1 core 1 
 
0.00 1.48 / 
675.31 1 HexNAc1Hex1Sia1 core 1 
 
0.00 1.17 / 
749.40 1 HexNAc2Hex2 core 2 
 
0.00 0.00 / 
895.39 1 HexNAc2Hex2Fuc1 core 1 / 3  / 
0.00 0.36 / 
966.40 1 HexNAc1Hex1Sia2 core 1 
 
0.00 0.09 / 
1040.43 1 HexNAc2Hex2Sia1 core 1  / 
18.81 17.40 0.93 
1040.43 1 HexNAc2Hex2Sia1 core 2 
 
2.33 1.44 0.62 
1040.44 1 HexNAc2Hex2Sia1 core 2 
 
6.65 7.91 1.19 
1186.49 1 HexNAc2Hex2Sia1Fuc1 core 2 / 4  / 
3.05 4.29 1.40 
1186.52 1 HexNAc2Hex2Sia1Fuc1 core 2 / 4  / 
0.51 0.15 0.30 
1227.53 1 HexNAc3Hex1Sia1Fuc1 core 2 / 4  / 
0.00 2.47 / 
1331.49 1 HexNAc2Hex2Sia2 core 2 
 
0.00 1.32 / 
1331.52 1 HexNAc2Hex2Sia2 core 2 / 
0.99 0.20 0.20 
1331.57 1 HexNAc2Hex2Sia2 core 2 
 
2.90 1.01 0.35 
1389.56 1 HexNAc3Hex2Sia1Fuc1 core 2 / 4  / 
26.90 45.91 1.71 
1389.58 1 HexNAc3Hex2Sia1Fuc1 core 2 / 4  / 
0.00 0.00 / 
1405.55 1 HexNAc3Hex3Sia1 core 2 / 4  / 
0.00 0.10 / 
1405.55 1 HexNAc3Hex3Sia1 core 2 / 4  / 
0.00 1.10 / 
1405.58 1 HexNAc3Hex3Sia1 core 2 / 4  / 
0.00 0.00 / 
1405.59 1 HexNAc3Hex3Sia1 core 2 / 4  / 
1.84 0.31 0.17 
1477.56 1 HexNAc2Hex2Sia2Fuc1 core 2 / 4 / 
3.01 0.57 0.19 
1477.58 1 HexNAc2Hex2Sia2Fuc1 core 2 / 4 / 
1.28 0.00 0.00 
1477.60 1 HexNAc2Hex2Sia2Fuc1 core 2 / 4  / 
1.49 0.17 0.11 
1696.62 2 HexNAc3Hex3Sia2 core 2 / 4  / 
0.00 2.17 / 
1696.63 2 HexNAc3Hex3Sia2 core 2 
 
1.81 0.00 0.00 
1696.66 2 HexNAc3Hex3Sia2 core 2 / 4  / 
0.60 0.00 0.00 
2061.76 2 HexNAc4Hex4Sia2 core 2 / 4  / 
1.46 0.00 0.00 
2061.79 2 HexNAc4Hex4Sia2 core 2 / 4  / 
1.61 0.44 0.27 
2061.80 2 HexNAc4Hex4Sia2 core 2 / 4 /  
10.19 4.86 0.48 
Total: 100 100 
 
 
5. Sialoproteomic analysis 
5.1 Cell lysis, protein digestion and iTRAQ labeling 
Cell pellets were redissolved in ice-cold Na2CO3 buffer (0.1 M, pH 11) supplemented with protease 
inhibitor (Roche complete EDTA free), PhosSTOP phosphatase inhibitor cocktail (Roche) and 10 mM 
sodium pervanadate on ice. The suspensions were tip probe sonicated for 20 s (amplitude = 50%) twice 
and incubated at 4°C for 1h. The lysates were then centrifuged at 100,000 × g for 90 min at 4°C to enrich 
membrane proteins (pellet). The pellets were washed with 50 mM triethylammonium bicarbonate 
(TEAB) to remove any remaining soluble protein. Membrane fraction was resuspended directly in 6 M 
urea and 2 M thiourea, reduced in 10 mM DTT for 30 min and then alkylated in 20 mM IAA for 30 min at 
room temperature in the dark. 
Samples were incubated with endoproteinase Lys-C (Wako, Osaka, Japan) for 2 h (1:100 w/w). Following 
the incubation, the samples were diluted 8 times with 50 mM TEAB (pH 8) and trypsin was added at a 
ratio of 1:50 (w/w) and left overnight at room temperature. Trypsin digestion was stopped by the 
addition of 2% formic acid and then the samples were centrifuged at 14,000 × g for 10 min to precipitate 
any lipids present in the sample. The supernatant was purified using in-house packed staged tips with a 
mixture of Poros R2 and Oligo R3 reversed phase resins (Applied Biosystem, Foster City, CA, USA). 
Briefly, a small plug of C18 material (3 M Empore) was inserted in the end of a P200 tips, followed by 
packing of the stage tip with the resins (resuspended in 100% ACN) by applying gentle air pressure. The 
acidified samples were loaded onto the micro-column after equilibration of the column with 0.1% 
trifluoroacetic acid (TFA), washed twice with 0.1% TFA and peptides were eluted with 60% ACN/0.1% 
TFA. A small amount of purified peptides (1 μl) from each sample was subjected to Qubit assay to 
determine the concentration, while the remaining samples were dried by vacuum centrifugation. 
Afterwards, peptides were redissolved in dissolution buffer and a total of 150 μg for each condition was 
labeled with 4-plex iTRAQTM (Applied Biosystems, Foster City, CA) as described by the manufacturer. 
After labeling, the samples were mixed 1:1:1:1 and lyophilized by vacuum centrifugation.  
5.2 Sialic acid containing glycopeptide enrichment by TiSH protocol 
The method used for sialylated glycopeptides enrichment is a modification of the TiSH protocol [6] 
described in [7, 8]. Briefly, samples were resuspended in loading buffer (1 M glycolic acid, 80% ACN, 5% 
TFA) and incubated with TiO2 beads (GL Sciences, Japan, 10 μm; using a total of 0.6 mg TiO2 beads per 
100 μg of peptides). The supernatant containing the unmodified peptides was carefully separated. The 
TiO2 beads were sequentially washed with loading buffer, washing buffer 1 (80% ACN, 1% TFA) and 
washing buffer 2 (20% ACN, 0.1% TFA), saving the washings with the previous supernatant. The bound 
peptides were eluted with 1.5% ammonium hydroxide by shaking for 15 min. The eluted fraction 
containing the phosphopeptides and sialylated glycopeptides was dried by vacuum centrifugation and 
subjected to an enzymatic deglycosylation in 20 mM TEAB buffer using 500 U of PNGase F (New England 
Biolabs, Ipswich, MA) and 0.1 U of Sialidase A (Prozyme, Hayward, CA) overnight at 37°C.  
To separate phosphorylated peptides and formerly glycosylated peptides, the samples were subjected 
to a second TiO2 enrichment procedure to separate phosphorylated from deglycosylated peptides. The 
supernatant containing the deglycosylated peptides was saved and the beads were washed with 50% 
ACN, 0.1% TFA. The washing was added to the supernatant. The deglycosylated fraction was desalted on 
Oligo R3 staged tip column and dried prior to the HILIC fractionation [7]. All fractions were dried by 
vacuum centrifugation prior nLC-MS/MS analysis.  
5.3 Sialic acid containing glycopeptide analysis by nLC-MS/MS 
Samples were resuspended in 6 µL of 0.1% TFA for analysis. Peptides were loaded on an in-house 
packed Reprosil-Pur C18-AQ (2 cm x 100 µm, 5 µm; Dr. Maisch GmbH, Germany) pre-column and 
separated on an in-house packed Reprosil-Pur C18-AQ (17 cm x 75 µm, 3 µm; Dr. Maisch GmbH, 
Germany) column using an Easy-nLC II system (Thermo Scientific, Bremen, Germany) and eluted at a 
flow of 250 nL/min. Mobile phase was 95% acetonitrile (B) and water (A) both containing 0.1% formic 
acid. Depending on the samples, gradient was from 1% to 30% solvent B in 80 or 110 min, 30 - 50% B in 
10 min, 50 - 100% B in 5 min and 8 min at 100% B. Mass spectrometric analyses were performed in an 
Orbitrap Fusion Tribrid system (Thermo Scientific, Bremen, Germany). MS scans (400 – 1200 m/z) were 
acquired in the orbitrap at a resolution of 120000 at 200 m/z for a AGC target of 5 x 105 ions and a 
maximum injection time of 60 ms. Data-dependent HCD MS/MS analysis at top speed of the most 
intense ions were performed at a resolution of 30000 at 200 m/z for a AGC target of 5 x 104 and a 
maximum injection time of 150 ms using the quadrupole to isolate the ions and an isolation window of 
1.2 m/z, a NCE of 38% and a dynamic exclusion of 20 s. 
The raw data were processed and quantified by Proteome Discoverer (version 1.4.1.14, Thermo 
Scientific) against SwissProt and Uniprot human reference databases by using Mascot (v2.3.02, Matrix 
Science Ltd, London, UK) and Sequest HT, respectively. Database searches were performed using the 
following parameters: precursor mass tolerance of 10 ppm, product ion mass tolerance of 0.02 Da, 1 
missed cleavages for trypsin, carbamidomethylation of Cys and iTRAQ labelling on protein N-terminal 
and Lys as fixed modifications, and phosphorylation on S/T/Y and deamidation of Asn as dynamic 
modifications. The iTRAQ datasets were quantified using the centroid peak intensity with the “reporter 
ions quantifier” node. Only peptides with up to a q-value of 0.01 (Percolator), Mascot and Sequest HT 
rank 1, Sequest HT ΔCn of 0.1, cut off value of Mascot score ≥  18 and a cut-off value of XCorr score for 
charge states of +1, +2, +3, and +4 higher than 1.5, 2, 2.25 and 2.5, respectively, were considered for 
further analysis. 
5.4 Data normalization and significance analysis  
Three biological replicates were analysed and submitted to the statistical analysis. The log2 values of the 
measured intensities were normalized by the median. Modified peptides were merged with the R Rollup 
function (http://www.omics.pnl.gov) allowing for one-hit-wonders and using the mean of the 
normalized intensities for each peptide. Quantification of proteins was obtained by merging the un-
modified peptides with the R Rollup function considering at least 2 unique peptides not allowing for 
one-hit-wonders and using the mean of the intensities. Then the mean over the experimental conditions 
for each peptide in each replicate was subtracted in order to merge data from different iTRAQ runs. 
Formerly sialylated glycopeptides containing the consensus motif for N-linked glycosylation (NXS/T/C; 
where X # P) were normalized based on the protein expression in each of the replicates. Significant 
up/down-regulations between experimental conditions were calculated allowing a false discovery rate 
of 0.05. Therefore, we applied combined limma and rank product tests [9], subsequently corrected for 
multiple testing according to Storey. 
Since spontaneous deamidation is frequently observed for asparagine residues, especially when the C-
terminal amino acid is glycine (NG), the sites with NGS/T/C are considered as only potential 
glycosylation. However, in order to reduce the contribution from spontaneous deamidation in the final 
list, we sort first for the N-linked consensus site (NXS/T/C) and then we filter for proteins that are 
membrane-associated in order to exclude intracellular proteins that are not N-linked glycosylated.  
 
 
 
Table 5: Proteins with increased N-glycan sialylation 
List of significantly increased sialylated N-glycan modified peptides in the ST3GAL4 overexpressing cells 
compared to mock control shown with accession number, protein name, peptide sequence and the 
identified N-glycan site. The fold in increase, p-value and the protein’s functional group are also 
presented.  AM: Adhesion and migration; E: Metabolic enzyme; RS: Receptor and signaling; T: 
Trafficking; TT: Transmembrane transporter; P: Protease; O: Others. 
Accession 
number 
Protein name Sequence 
N-glycan 
site 
ST3GAL4 
/Mock 
Limma&Rank  
(p-value) 
Func. 
Grp. 
O15031 Plexin-B2 
ISVAGRNdeCSFQPER N844 2.89 0.0342 
RS 
ALSNdeISLR N127 2.08 0.0358 
O60637 Tetraspanin-3  
TYNdeGTNdePDAASR N127 2.96 0.0358 
RS 
TYNdeGTNPDAASR N127 2.98 0.0433 
O75882 Attractin GICNdeSSDVR N300 2.35 0.0342 IR 
P02786 
Transferrin 
receptor protein 1 
KDFEDLYTPVNdeGSIVIVR N251 1.72 0.0433 TT 
P05026 
Sodium/potassium-
transporting 
ATPase subunit 
beta-1 
FKLEWLGNdeCSGLNDETYGYK N158 2.79 0.0479 TT 
P06213 Insulin receptor HNdeLTITQGK N445 2.45 0.0479 RS 
P06731 
Carcinoembryonic 
antigen-related cell 
adhesion molecule 
5 
TLTLFNdeVTR N204 2.67 0.0342 
AM 
TLTLFNVTRNdeDTASYK N208 3.11 0.0342 
P06756 Integrin alpha-V 
ISSLQTTEKNdeDTVAGQGER N874 4.02 0.0342 
AM 
NdeMTISR N554 4.02 0.0342 
P07602 Prosaposin TNdeSTFVQALVEHVKEECDR N215 2.59 0.0479 O 
P08962 CD63 antigen CCGAANdeYTDWEK N150 1.94 0.0394 RS 
P10909 Clusterin EIRHNdeSTGCLR N291 2.12 0.0342 O 
P11117 
Lysosomal acid 
phosphatase 
QTPEYQNdeESSR N177 3.05 0.0383 E 
P12821 
Angiotensin-
converting enzyme 
IGLLDRVTNdeDTESDINYLLK N445 2.62 0.0456 P 
P13473 
Lysosome-
associated 
membrane 
glycoprotein 2 
LNdeSSTIK N275 3.09 0.0342 
AM VASVINdeINPNdeTTHSTGSCR N253 1.96 0.0358 
VASVININPNdeTTHSTGSCR N257 2.06 0.0456 
P13688 
Carcinoembryonic 
antigen-related cell 
adhesion molecule 
1 
NdeQSLPSSER N363 2.76 0.0479 AM 
P13726 Tissue factor 
RNdeNTFLSLR N169 5.52 0.0342 
P 
NdeNTFLSLR N169 5.76 0.0358 
P18564 Integrin beta-6 EVEVNdeSSK N463 3.71 0.0479 AM 
P21589 5'-nucleotidase LDNdeYSTQELGK N333 1.67 0.0479 E 
P26006 Integrin alpha-3 ELAVPDGYTNdeRTGAVYLCPLTAHK N86 2.68 0.0433 AM 
P30825 
High affinity 
cationic amino acid 
transporter 1 
LCLNNdeDTK N235 3.48 0.0297 
TT 
LCLNdeNdeDTK N234 3.01 0.0342 
P35613 Basigin ALMNdeGSESR N268 2.91 0.0342 P 
P42892 
Endothelin-
converting enzyme 
1 
NdeSSVEAFK N632 1.89 0.0394 
P 
DYYLNdeKTENEK N270 5.64 0.0479 
P43007 
Neutral amino acid 
transporter A 
VVTQNdeSSSGNdeVTHEK N201 2.58 0.0477 TT 
P46059 
Solute carrier 
family 15 member 
1 
NdeDSCPEVK N562 4.66 0.0358 TT 
P48960 CD97 antigen WCPQNSSCVNdeATACR N38 1.87 0.0479 AM 
P54760 
Ephrin type-B 
receptor 4 
CAQLTVNdeLTRFPETVPR N203 2.34 0.0342 RS 
Q04912 
Macrophage-
stimulating protein 
receptor 
LPEYVVRDPQGWVAGNdeLSAR N841 3.26 0.0358 RS 
Q08380 
Galectin-3-binding 
protein 
DAGVVCTNdeETR N125 2.43 0.0358 AM 
Q08722 
Leukocyte surface 
antigen CD47 
SDAVSHTGNdeYTCEVTELTREGETIIELK N111 6.51 0.0056 AM 
Q11206 ST3GAL4 LFGNdeYSR N61 5.77 0.0088 O 
Q12913 
Receptor-type 
tyrosine-protein 
phosphatase eta 
HGSNdeHTSTYDK N582 3.15 0.0342 
RS 
VSDNdeESSSNdeYTYK N391 2.94 0.0342 
VSDNESSSNdeYTYK N396 2.74 0.0383 
GPNdeGTEGASR N525 2.76 0.0427 
IHVAGETDSSNdeLNdeVSEPR N411 1.69 0.0479 
SNdeDTAASEYK N142 2.77 0.0479 
Q13641 
Trophoblast 
glycoprotein 
CVNRNdeLTEVPTDLPAYVR N81 1.85 0.0429 RS 
Q14108 
Lysosome 
membrane protein 
2 
ANIQFGDNdeGTTISAVSNdeK N105 2.03 0.0394 
T 
ANdeIQFGDNdeGTTISAVSNK N99 1.78 0.0479 
Q15043 
Zinc transporter 
ZIP14 
ALLNHLDVGVGRGNdeVTQHVQGHR N77 2.42 0.0479 TT 
Q15758 
Neutral amino acid 
transporter B(0) 
NdeITGTR N212 2.93 0.0479 TT 
Q7Z7H5 
Transmembrane 
emp24 domain-
containing protein 
4 
QYGSEGRFTFTSHTPGDHQICLHSNdeSTR N117 2.50 0.0479 T 
Q8N271 Prominin-2 ILRNdeVSECFLAR N725 3.11 0.0433 O 
Q92542 Nicastrin RPNdeQSQPLPPSSLQR N417 1.66 0.0483 P 
Q92673 
Sortilin-related 
receptor 
LTIVNdeSSVLDRPR N871 1.92 0.0479 
T 
SRNdeSTVEYTLNK N1986 1.67 0.0479 
Q9BXB1 
Leucine-rich 
repeat-containing 
G-protein coupled 
receptor 4 
TLDLSYNNIRDLPSFNdeGCHALEEISLQR N362 4.00 0.0358 RS 
Q9BXS4 
Transmembrane 
protein 59 
LFSICQFVDDGIDLNdeRTK N90 4.09 0.0342 T 
Q9H330 
Transmembrane 
protein 245 
ILGDKVNdeNTAVIEK N551 3.47 0.0433 O 
Q9H5V8 
CUB domain-
containing protein 
1 
ASVSFLNFNdeLSNCERK N270 3.33 0.0342 
AM IGTFCSNdeGTVSR N180 2.93 0.0358 
NdeVSGFSIANR N205 2.33 0.0358 
Q9HD43 Receptor-type NdeATTAHNPVR N203 6.86 0.0342 RS 
tyrosine-protein 
phosphatase H 
ETRNdeATTAPNPVR N381 2.93 0.0479 
NdeTTNTSVTAER N434 2.72 0.0479 
Q9P2B2 
Prostaglandin F2 
receptor negative 
regulator 
QRNdeNSWVK N525 3.60 0.0429 RS 
Q9UN76 
Sodium- and 
chloride-
dependent neutral 
and basic amino 
acid transporter 
B(0+) 
SPIVTHCNdeVSTVNdeK N174 2.44 0.0420 TT 
Q9Y639 Neuroplastin ANdeATIEVK N229 2.59 0.0429 AM 
 
Table 6: Proteins with decreased N-glycan sialylation 
List of significantly decreased sialylated N-glycan modified peptides in the ST3GAL4 overexpressing cells 
compared to mock control shown with accession number, protein name, peptide sequence and the 
identified N-glycan site, fold in increase and the p-value. 
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Accession 
number 
Protein name Sequence N-glycan site ST3GalIV/Mock 
Limma&Rank 
 (p-value) 
O14672 
Disintegrin and metalloproteinase 
domain-containing protein 10 
NdeISQVLEK N439 0.57 0.0149 
P07602 Proactivator polypeptide NdeSTKQEILAALEK N426 0.57 0.0474 
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